Fig. 1: Experimental design of Late and Early ART-suppressed SIV or SHIV-infected cohorts.
From: Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques
A Late ART study design: 7 rhesus monkeys were infected with either SIVmac251 or SHIV-SF162P3 (n = 4 and 3 animals/group, respectively) for at least a year (≥52 weeks). ART was initiated at week 0 and daily ART administration was maintained until the day of necropsy. B Early ART study design: 12 rhesus monkeys were infected with SIVmac251 for 1 week. Animals were maintained on daily ART suppression until the day of necropsy. C Plasma viral loads are shown for the Late ART (median line for SIVmac251 infected animals in red and median line for SHIV- SF162P3 infected animals in blue) and Early ART studies. Log SIV-RNA copies/ml are shown (LOD = 50 RNA copies/ml). Black lines indicate individual monkey values. ART, antiretroviral therapy.
